All‐cause mortality at 5 years · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes all‐cause mortality at 5 years compared with no chemotherapy (very low certainty).
1 finding from 1 review
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
All‐cause mortality at 5 years · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
All‐cause mortality 5.6 years · patients with diabetes mellitus
Tight glycaemic control showed no clear difference in all‐cause mortality 5.6 years compared with non‐tight control (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality or liver transplantation at two years · infants with biliary atresia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Time to death from any cause (here: overall mortality at 12‐month · advanced hormone‐sensitive prostate cancer
Early probably leads to lower time to death of any cause (here: all‐cause mortality at 5 years) compared with deferred AST (moderate certainty).
1 finding from 1 review
Death (all causes)
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review